HC Wainwright Has Negative Estimate for IPSC FY2027 Earnings

Century Therapeutics, Inc. (NASDAQ:IPSC – Free Report) – HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Century Therapeutics in a research report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.48) per share for the year, down from their previous forecast of ($0.47). The consensus estimate for Century Therapeutics’ current full-year earnings is ($0.51) per share.

A number of other analysts have also commented on IPSC. Wall Street Zen raised shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Weiss Ratings downgraded shares of Century Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, November 13th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $4.75.

Read Our Latest Research Report on IPSC

Century Therapeutics Trading Up 0.7%

NASDAQ IPSC opened at $1.38 on Tuesday. The stock’s 50-day moving average price is $1.61 and its two-hundred day moving average price is $2.05. The company has a market cap of $250.61 million, a PE ratio of -2.16 and a beta of 1.78. Century Therapeutics has a 1 year low of $0.46 and a 1 year high of $3.04.

Century Therapeutics (NASDAQ:IPSC – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Commodore Capital LP purchased a new stake in Century Therapeutics in the 1st quarter worth about $19,652,000. BlackRock Inc. purchased a new position in Century Therapeutics during the 2nd quarter valued at about $19,825,000. Seven Fleet Capital Management LP purchased a new position in Century Therapeutics during the 1st quarter valued at about $9,826,000. Trails Edge Capital Partners LP purchased a new position in Century Therapeutics during the 2nd quarter valued at about $10,130,674. Finally, Spruce Street Capital LP acquired a new position in shares of Century Therapeutics in the 2nd quarter valued at about $9,944,682. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

(Get Free Report)

Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.

Featured Stories

Earnings History and Estimates for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.